Impressive clinical results with the first device-based treatment for drug-resistant hypertension – the Symplicity Renal Denervation System from Ardian Inc. (now a subsidiary of Medtronic PLC) – has ignited something of a modern-day “gold rush” in the medical device industry. Just three years ago, Ardian was the only company working publicly in this area; but now, some observers estimate there are as many as 40 companies developing various device-based therapies for resistant hypertension, including most of the big names in the cardiovascular device arena – Medtronic, St. Jude Medical Inc., Boston Scientific Corp., Johnson & Johnson (J&J), and Medtronic Minimally Invasive Therapies – along with a large number of start-ups, all racing to stake a claim in this highly promising market.
It’s easy to see why the space is so attractive. According to the American Heart Association (AHA), one in three US adults has hypertension, which translates to an estimated prevalence...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?